✨ Free AI Report
Sagimet Biosciences Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Sagimet Biosciences Inc.
Company Research

Sagimet Biosciences Inc.: Business Overview, Financials & Competitive Analysis

Sagimet Biosciences is a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases resulting from dysfunctional metabolic pathway...

Analyst-debate audio for Sagimet Biosciences Inc.

AskCyborg analysts argue the bull and bear cases for Sagimet Biosciences Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
6/ 10Solid

Cyborg Score thesis

Early-stage biotech with promising FASN inhibitor portfolio targeting high-unmet-need metabolic diseases; Phase III progress...

Read the full analyst-debate transcript →
Industry Clinical-stage Biopharmaceuticals / Metabolic Disease Therapeutics
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 14, 2026
AI-Verified Research
30+ Page Report

Get the Latest Sagimet Biosciences Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Sagimet Biosciences Inc. Overview

Pro stress-test →

Sagimet Biosciences is a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases resulting from dysfunctional metabolic pathways. The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis.

Strategic Profile

Pro stress-test →

In addition to MASH, the company is evaluating denifanstat in acne and in select forms of cancer, with denifanstat being tested in a Phase III clinical trial for moderate to severe acne vulgaris and a Phase III trial for recurrent glioblastoma multiforme in combination with bevacizumab. Sagimet has a global exclusive license with TAPI for innovative forms of resmetirom API to support a fixed-dose combination program combining resmetirom with denifanstat, with a Phase 3 study planned.

Competitive Landscape

Pro stress-test →

Sagimet operates in the metabolic dysfunction-associated steatohepatitis (MASH) and acne treatment space. Competitors include Madrigal Pharmaceuticals and other FASN inhibitor developers. The company differentiates through its multi-indication platform (MASH, acne, oncology) and partnership strategies.

Industry Context

Sagimet Biosciences Inc. operates in Clinical-stage Biopharmaceuticals / Metabolic Disease Therapeutics.

Key facts

Founded: 2006 · Headquarters: San Mateo, California · Market cap: $167-252M

What the analysts stress-tested

The top findings that survived the multi-agent debate for Sagimet Biosciences Inc..

  • Positive Phase 1 pharmacokinetic results announced Dec 18, 2025 for denifanstat-resmetirom combination in healthy adults
  • China regulatory approval for denifanstat (ASC40) for acne in December 2025 positions international expansion
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • Mar 2026Management participating in TD Cowen, Leerink, and Citizens investor conferences
  • Jan 2026Secondary analysis presented at MASH-TAG Conference showing significant fibrosis improvement in F3 MASH patients
  • +1 moreTrack every material event for Sagimet Biosciences Inc. as it happens. Explore monitoring →
Get alerted when Sagimet Biosciences Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

ResmetiromFGF21 agonist for MASH→Obeticholic acidFXR agonist for MASH→Pioglitazone/Vitamin ETraditional NASH treatment options→

Compare Sagimet Biosciences Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Sagimet Biosciences Inc. operates in Clinical-stage Biopharmaceuticals / Metabolic Disease Therapeutics. See how the rest of the sector scores on the Cyborg framework.

Browse Clinical-stage Biopharmaceuticals / Metabolic Disease Therapeutics research →
NEW · MCP server

Ask your AI assistant about Sagimet Biosciences Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Sagimet Biosciences Inc. and its top competitor on Cyborg Score”
“What did Sagimet Biosciences Inc. do this quarter?”
“Is Sagimet Biosciences Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Sagimet Biosciences Inc. do?+
Sagimet Biosciences is a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases resulting from dysfunctional metabolic pathway...
What is Sagimet Biosciences Inc.'s Cyborg Score?+
Sagimet Biosciences Inc. has a Cyborg Score of 6/10 (Solid). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Sagimet Biosciences Inc.'s main competitors?+
Named competitors include Resmetirom, Obeticholic acid, Pioglitazone/Vitamin E. The full competitive landscape is in the AskCyborg report.
How can I get the full Sagimet Biosciences Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Sagimet Biosciences Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Sagimet Biosciences Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Clinical-stage Biopharmaceuticals research

Companies in the same sector and named competitors, ranked by Cyborg Score.

7AtaiBeckley Inc.7NervGen Pharma Corp7Trevi Therapeutics, Inc.6Disc Medicine, Inc.4OnKure Therapeutics, Inc.4Pliant Therapeutics, Inc.3Applied Therapeutics, Inc.